Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.59 |
| ▸ | CES1 | P23141 | 4/20 | 0.59 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.56 |
| ▸ | PPARG | P37231 | 7/20 | 0.56 |
| ▸ | PPARD | Q03181 | 7/20 | 0.56 |
| ▸ | PPARA | Q07869 | 7/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636538 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL10937134 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL25753802 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL7937351 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL22756799 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL13129756 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL13636095 | 1.00 | CES2 (0.59) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL3506754 | 0.97 | — | — | |
| SCHEMBL2554932 | 0.89 | — | — | |
| SCHEMBL8924604 | 0.87 | TERT (0.66) | PPARGPPARDPPARAPTPN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435963-B2 | Weight loss compositions and uses thereof | ENERGY BEVERAGES LLC | 2013-05-07 | — | — | US | claimed |
| US-20100081626-A1 | WEIGHT LOSS COMPOSITIONS AND USES THEREOF | ENERGY BEVERAGES LLC | 2010-04-01 | — | — | US | claimed |
| US-20240241020-A1 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | LONZA SALES AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240241020-A1 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | LONZA SALES AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240209368-A1 | EXTRACELLULAR VESICLE COMPOSITIONS | LONZA SALES AG (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240209368-A1 | EXTRACELLULAR VESICLE COMPOSITIONS | LONZA SALES AG (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240066433-A1 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | LONZA SALES AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-20240066433-A1 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | LONZA SALES AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-20230366794-A1 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | CODIAK BIOSCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230366794-A1 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | CODIAK BIOSCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364127-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | CODIAK BIOSCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230002764-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CODIAK BIOSCIENCES, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220387906-A1 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | CODIAK BIOSCIENCES, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220323519-A1 | COMPOSITIONS OF EXOSOMES AND AAV | CODIAK BIOSCIENCES, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220218811-A1 | METHODS OF TREATING TUBERCULOSIS | CODIAK BIOSCIENCES, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220168415-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | CODIAK BIOSCIENCES, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220017907-A1 | ENGINEERED EXTRACELLULAR VESICLES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20190284129-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2019-09-19 | — | — | US | disclosed |
| US-8435963-B2 | Weight loss compositions and uses thereof | ENERGY BEVERAGES LLC | 2013-05-07 | — | — | US | disclosed |
| US-20100081626-A1 | WEIGHT LOSS COMPOSITIONS AND USES THEREOF | ENERGY BEVERAGES LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209368-A1 | EXTRACELLULAR VESICLE COMPOSITIONS | EXOSC5, EXOSC9, EXOSC4 | CES2 3861/4885CES1 2563/4885GPR84 4005/4885 |
| US-20190284129-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | APOB, ALOX12, NR1H2 | CES2 2082/4885CES1 153/4885GPR84 699/4885 |
| US-20220323519-A1 | COMPOSITIONS OF EXOSOMES AND AAV | EXOSC5, EXOSC9, EXOSC10 | CES2 3359/4885CES1 2648/4885GPR84 3461/4885 |
| US-20220218811-A1 | METHODS OF TREATING TUBERCULOSIS | IFNG, IL2, MMP12 | CES2 4037/4885CES1 3727/4885GPR84 1583/4885 |
| US-20220017907-A1 | ENGINEERED EXTRACELLULAR VESICLES AND USES THEREOF | EXOSC5, EXOSC10, EXOSC4 | CES2 3814/4885CES1 3490/4885GPR84 2331/4885 |
| US-20220168415-A1 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | HAVCR2, CD74, HMGB1 | CES2 2820/4885CES1 2096/4885GPR84 1624/4885 |
| US-20230364127-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | STAT6, STAT1, STAT3 | CES2 4729/4885CES1 2095/4885GPR84 3030/4885 |
| US-20230002764-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, CNBP, EXOSC5 | CES2 980/4885CES1 238/4885GPR84 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.